4//SEC Filing
ROCKLAGE SCOTT M 4
Accession 0001415889-25-022806
CIK 0001516551other
Filed
Aug 21, 8:00 PM ET
Accepted
Aug 22, 7:05 PM ET
Size
25.1 KB
Accession
0001415889-25-022806
Insider Transaction Report
Form 4
5AM Ventures II LP
10% Owner
Transactions
- Sale
Common Stock
2025-08-21$3.57/sh−2,314$8,261→ 63,963 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−163,979$560,808→ 1,457,064 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−6,470$22,127→ 57,493 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−58,642$209,352→ 1,621,043 total(indirect: By 5AM Ventures II, L.P.)
Holdings
- 8,167,206(indirect: By 5AM Ventures VII, L.P.)
Common Stock
PARMAR KUSH
10% Owner
Transactions
- Sale
Common Stock
2025-08-22$3.42/sh−163,979$560,808→ 1,457,064 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−6,470$22,127→ 57,493 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−58,642$209,352→ 1,621,043 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−2,314$8,261→ 63,963 total(indirect: By 5AM Co-Investors II, L.P.)
Holdings
- 8,167,206(indirect: By 5AM Ventures VII, L.P.)
Common Stock
ROCKLAGE SCOTT M
10% Owner
Transactions
- Sale
Common Stock
2025-08-22$3.42/sh−163,979$560,808→ 1,457,064 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−2,314$8,261→ 63,963 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−6,470$22,127→ 57,493 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−58,642$209,352→ 1,621,043 total(indirect: By 5AM Ventures II, L.P.)
Holdings
- 8,167,206(indirect: By 5AM Ventures VII, L.P.)
Common Stock
5AM Ventures VII, L.P.
10% Owner
Transactions
- Sale
Common Stock
2025-08-21$3.57/sh−2,314$8,261→ 63,963 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−6,470$22,127→ 57,493 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−58,642$209,352→ 1,621,043 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−163,979$560,808→ 1,457,064 total(indirect: By 5AM Ventures II, L.P.)
Holdings
- 8,167,206(indirect: By 5AM Ventures VII, L.P.)
Common Stock
DIEKMAN JOHN D
10% Owner
Transactions
- Sale
Common Stock
2025-08-21$3.57/sh−58,642$209,352→ 1,621,043 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−2,314$8,261→ 63,963 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−163,979$560,808→ 1,457,064 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−6,470$22,127→ 57,493 total(indirect: By 5AM Co-Investors II, L.P.)
Holdings
- 8,167,206(indirect: By 5AM Ventures VII, L.P.)
Common Stock
5AM Partners VII, LLC
10% Owner
Transactions
- Sale
Common Stock
2025-08-21$3.57/sh−58,642$209,352→ 1,621,043 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−6,470$22,127→ 57,493 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−2,314$8,261→ 63,963 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−163,979$560,808→ 1,457,064 total(indirect: By 5AM Ventures II, L.P.)
Holdings
- 8,167,206(indirect: By 5AM Ventures VII, L.P.)
Common Stock
5AM Partners II, LLC
10% Owner
Transactions
- Sale
Common Stock
2025-08-21$3.57/sh−58,642$209,352→ 1,621,043 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−163,979$560,808→ 1,457,064 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−2,314$8,261→ 63,963 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−6,470$22,127→ 57,493 total(indirect: By 5AM Co-Investors II, L.P.)
Holdings
- 8,167,206(indirect: By 5AM Ventures VII, L.P.)
Common Stock
5AM CO-INVESTORS II LP
10% Owner
Transactions
- Sale
Common Stock
2025-08-21$3.57/sh−2,314$8,261→ 63,963 total(indirect: By 5AM Co-Investors II, L.P.) - Sale
Common Stock
2025-08-21$3.57/sh−58,642$209,352→ 1,621,043 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−163,979$560,808→ 1,457,064 total(indirect: By 5AM Ventures II, L.P.) - Sale
Common Stock
2025-08-22$3.42/sh−6,470$22,127→ 57,493 total(indirect: By 5AM Co-Investors II, L.P.)
Holdings
- 8,167,206(indirect: By 5AM Ventures VII, L.P.)
Common Stock
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- [F3]The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
Documents
Issuer
Skye Bioscience, Inc.
CIK 0001516551
Entity typeother
Related Parties
1- filerCIK 0001219014
Filing Metadata
- Form type
- 4
- Filed
- Aug 21, 8:00 PM ET
- Accepted
- Aug 22, 7:05 PM ET
- Size
- 25.1 KB